Literature DB >> 28029697

Validation of the italian version of the 15-item Myasthenia Gravis Quality-of-Life questionnaire.

Alberto Raggi1, Matilde Leonardi1, Roberta Ayadi1, Carlo Antozzi2, Lorenzo Maggi2, Fulvio Baggi2, Renato Mantegazza2.   

Abstract

INTRODUCTION: In this study we assess the Italian version of the 15-item Myasthenia Gravis Quality-of-Life questionnaire (MG-QOL15).
METHODS: The validation protocol included the MG-QOL15, the 36-item Short Form (SF-36), the Besta Neurological Institute Rating Scale for Myasthenia Gravis, and the MG-Composite. We used the Cronbach α to test reliability, the Spearman correlation to test short-term test-retest, the Kruskal-Wallis test to assess differences in MG-QOL15 between patients with different disease severity, and the Wilcoxon signed-rank test to assess sensitivity to change.
RESULTS: Seventy-two patients were enrolled in the study. The mean MG-QOL15 score was 15.2 ± 12.2, with α = 0.93 and test-retest correlation = 0.93. Compared with the SF-36, the MG-QOL15 was superior in differentiating patients with different MG types (P = 0.041) and severity (P = 0.004), showed higher sensitivity to change (P = 0.003 for improved and P = 0.024 for worsened patients), and had higher correlations with the MG-Composite (rho = 0.367 vs. -0.213 and -0.154).
CONCLUSION: The Italian version of the MG-QOL15 is valid, reliable, stable, and sensitive to changes. Muscle Nerve 56: 716-720, 2017.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  INCB-MG; MG-QOL15; SF-36; myasthenia gravis; reliability; validity

Mesh:

Year:  2017        PMID: 28029697     DOI: 10.1002/mus.25545

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

Review 1.  Immunotherapy in myasthenia gravis in the era of biologics.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

2.  Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII).

Authors:  Francesca Pasqualin; Carolina Barnett; Silvia Vittoria Guidoni; Elisa Albertini; Mario Ermani; Domenico Marco Bonifati
Journal:  Neurol Sci       Date:  2021-09-09       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.